In 2015, the results of the CheckMate 067 study led to the approval of the combination of nivolumab plus ipilimumab in patients with untreated advanced melanoma with and without BRAF V600 mutation.33 This trial compared the combination regimen vs nivolumab or ipilimumab monotherapy as the frontline treatment for these patients. Here, BRAF is linked to melanoma.